New data confirm that Prexige® (lumiracoxib) is effective in relieving symptoms of osteoarthritis
Basel, Switzerland, 20 June 2003 - Data from key clinical Phase III studies presented for the first time at EULAR, the European League Against Rheumatism annual congress in Lisbon, demonstrate that Prexige® (lumiracoxib), a novel COX-2 selective inhibitor, provides effective relief of the symptoms of osteoarthritis (OA).
Please see full press release under the following link:
